RYTM Dec 2025 40.000 call
| Previous close | 13.60 |
| Open | N/A |
| Bid | 10.00 |
| Ask | 14.40 |
| Strike | 40.00 |
| Expiry date | 2025-12-19 |
| Day's range | 13.60 - 13.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireRhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and av
Simply Wall St.While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week
It hasn't been the best quarter for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shareholders, since the share price...
- GlobeNewswire
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centresBOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that re
